Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Ependymoma × CNS × Clear all

Phase

Phase 1 66 Phase 2 60 Phase NA 15 Phase 1/2 12 Phase EARLY_PHASE1 6 Phase 3 4 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 15 Brain Neoplasms 12 Glioma 7 Carcinoma, Non-Small-Cell Lung 6 Recurrence 4 Astrocytoma 4 Spinal Cord Neoplasms 3 Neoplasms 3 Colorectal Neoplasms 3 Thyroid Carcinoma, Anaplastic 2 Thyroid Cancer, Papillary 2 Ovarian Neoplasms 2 Oligodendroglioma 2 Neurofibromatosis 1 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Multiple Myeloma 2 Medulloblastoma 2 Lung Neoplasms 2 Laryngeal Neoplasms 2 Hematologic Neoplasms 2 Erdheim-Chester Disease 2 Central Nervous System Neoplasms 2 cyclopia sequence 1 Vitamin D Deficiency 1 Thyroid Neoplasms 1 Stroke 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Injuries 1 Somatostatinoma 1

Interventions

trofosfamide 1 Thiotepa 1 Temozolomide 1 Etoposide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00749723 2018-07-20

HIT-REZ-2005

University Hospital, Bonn

Phase 2/3 Completed

Brain Neoplasms, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡